RSV Vaccine Availability Adults: A Comprehensive Guide for 2025
Estimated reading time: 8 minutes
- Three RSV vaccines are now available for at-risk adults: Arexvy, Abrysvo, and mResvia.
- The CDC recommends vaccination for adults 75+, and those 50-74 with increased risk factors.
- Pfizer’s Abrysvo and Moderna’s mResvia are approved for adults 18-49 with increased risk, pending broader ACIP recommendations.
- Vaccination is ideally done in late summer/early fall, before the peak RSV season.
- The vaccines are generally safe and effective, though side effects may occur.
- RSV Vaccines Now Widely Available for At-Risk Adults
- CDC Recommendations and Eligible Groups: Who Should Get Vaccinated?
- Expanding Horizons: Vaccination for Younger Adults
- Understanding the Available RSV Vaccines: A Detailed Comparison
- Vaccination Timing and Dosing: When and How Often?
- Safety and Effectiveness: Weighing the Benefits and Risks
- Availability and Cost: Accessing the Vaccine
- Practical Takeaways and Actionable Advice
- Call to Action
RSV Vaccines Now Widely Available for At-Risk Adults
Three distinct RSV vaccines are now available in the United States for adults: Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna). These vaccines represent a significant advancement in protecting vulnerable adult populations from the potentially severe consequences of RSV infection. This increased availability marks a turning point in preventative care for this significant public health concern.
CDC Recommendations and Eligible Groups: Who Should Get Vaccinated?
The Centers for Disease Control and Prevention (CDC) provides clear recommendations regarding RSV vaccination for adults. Currently, a single dose of any FDA-licensed RSV vaccine is recommended for:
- Adults aged 75 and older: This age group faces the highest risk of severe RSV disease and hospitalization. Vaccination is strongly encouraged for all individuals in this cohort.
- Adults aged 50–74 with increased risk of severe RSV disease: This group includes individuals with one or more of the following risk factors:
- Chronic cardiovascular disease
- Chronic lung or respiratory disease (including asthma, COPD, cystic fibrosis)
- End-stage renal disease
- Diabetes mellitus with complications
- Certain neurologic or neuromuscular conditions (e.g., cerebral palsy, muscular dystrophy)
- Chronic liver disease
- Weakened immune system (due to disease or medication)
- Residents of nursing homes or long-term care facilities
Expanding Horizons: Vaccination for Younger Adults
The FDA has expanded the approval of Pfizer’s Abrysvo and Moderna’s mResvia to include adults aged 18-49 years who are at increased risk for RSV-Lower Respiratory Tract Disease (LRTD). However, it’s crucial to note that as of February 2025, the Advisory Committee on Immunization Practices (ACIP) has not yet issued a population-based recommendation for this younger age group. Further data is being collected to inform broader recommendations in the future. This highlights the ongoing evolution of RSV vaccine policy and the importance of staying informed about the latest updates.
Understanding the Available RSV Vaccines: A Detailed Comparison
Let’s delve deeper into the specifics of each currently available RSV vaccine:
- Arexvy (GSK): This recombinant protein subunit vaccine was the first to receive FDA approval in May 2023. Initially approved for individuals 60 and older, its indication has expanded to include adults aged 50–59 years who are at increased risk for RSV-LRTD. Arexvy contains an adjuvant, a substance that enhances the immune response to the vaccine.
- Abrysvo (Pfizer): Another recombinant protein subunit vaccine, Abrysvo received FDA approval in May 2023 for adults 60 years and older. Its approval has expanded significantly to include adults aged 18 to 59 years who are at increased risk for RSV-LRTD, making it the broadest adult indication among currently approved RSV vaccines. Abrysvo is bivalent and does not contain an adjuvant. Importantly, it’s also approved for pregnant individuals at 32–36 weeks gestational age to protect their infants from birth through six months of age.
- mResvia (Moderna): This mRNA vaccine, approved in May 2024, is a newer addition to the market. It’s approved for older adults and, similar to Abrysvo, adults aged 18-49 years who are at increased risk for RSV-LRTD.
There is no preferential recommendation among the three vaccines for eligible adults; patients should receive whichever FDA-licensed vaccine is available and appropriate for their age and risk factors. Consult with your healthcare provider to discuss the best option for you.
Vaccination Timing and Dosing: When and How Often?
Eligible adults can receive the RSV vaccine at any time of year. However, the optimal timing is during late summer and early fall (typically August–October), preceding the usual peak RSV season. This allows for maximum protection during the months when RSV transmission is most prevalent.
Currently, the RSV vaccine is a single-dose vaccine. Individuals who have already received a dose do not need another dose at this time. The duration of protection from a single dose is estimated to be at least two years for adults aged 50 and older. Future recommendations regarding booster doses will be determined through ongoing surveillance and research.
Safety and Effectiveness: Weighing the Benefits and Risks
Extensive clinical trials have demonstrated the significant effectiveness of RSV vaccines in preventing RSV-associated lower respiratory tract disease and hospitalizations in older adults. For example, Abrysvo showed approximately 79% effectiveness in preventing RSV-associated emergency department encounters and 73% effectiveness in preventing hospitalizations in adults 60 and older during the 2023–2024 RSV season. Arexvy similarly demonstrated substantial efficacy.
While generally well-tolerated, common side effects reported in clinical trials include fatigue, headache, pain at the injection site, and muscle pain. A small but real risk of Guillain-Barré syndrome (GBS) has been identified as a safety signal following RSV vaccination, and further investigation is underway. Individuals with weakened immune systems may have a reduced immune response to the vaccine. Discuss any concerns regarding side effects with your healthcare provider before vaccination.
Availability and Cost: Accessing the Vaccine
RSV vaccines are widely available at major retail pharmacies and through healthcare providers nationwide. Under the Inflation Reduction Act, Medicare Part D beneficiaries typically have no out-of-pocket costs for the vaccine. Commercially insured patients may also have coverage with no cost-sharing when the vaccine is administered in-network. It’s always advisable to contact your insurance provider or pharmacist to confirm coverage details.
Practical Takeaways and Actionable Advice
- Talk to your doctor: If you are 50 years or older, or if you are younger but have an increased risk of severe RSV, discuss the benefits of RSV vaccination with your physician.
- Schedule your vaccination: The optimal time for vaccination is during late summer and early fall, but it’s never too late to get vaccinated.
- Understand your coverage: Check with your insurance provider or pharmacist to clarify your out-of-pocket costs.
- Stay informed: Keep up-to-date on the latest recommendations and developments regarding RSV vaccines by consulting the CDC website and other reputable sources.
Call to Action
Protect yourself and your loved ones from the serious consequences of RSV. Contact us today to schedule your RSV vaccination or to learn more about our comprehensive vaccination services. We are dedicated to providing expert guidance and accessible care to help you stay healthy.
